




Key Indicators:

🕒 Date: Jun 26, 2025

Stock Price	\$158.7	EPS Actual	11.1	Beta (5Y)	1.29
Upside	+\$40.6	EPS Estimate	12.0	Revenue	15.5B
Fair Value	\$199.3	EPS Revisions (90d)	↑ 1 ↓ 14	Revenue Forecast	16.1B
52-Week Range	\$134.6 - \$252.9	PEG Ratio	78.3	1-Year Change	-0.25%
Market Cap	27.5B	FCF Yield	0.08	Div Yield	0%
P/E Ratio	20.7	EV / EBITDA	13.7	Div. Growth Streak	-
P/E (Fwd.)	13.2	Book / Share	33.9	Next Earnings	2025-07-29

5-Year Chart



Financial health is determined by ranking the company on over 100 indicators compared to other companies in its sector that operate in similar economic markets.

Financial Health

5.9/10

Growth Rating



8.2/10

Profitability Rating



5.4/10

Cash Flow Rating



Executive Summary

IQVIA Holdings Inc. is a global leader in healthcare analytics and clinical research services, operating across more than 100 countries with a comprehensive portfolio of technology-driven healthcare solutions.

The company has demonstrated resilient performance with **Q1 2025 revenue reaching \$3.83 billion**, representing a 2.5% year-over-year growth, while adjusted EPS of \$2.70 exceeded analyst expectations. IQVIA maintains a **strong market position** through its diverse service offerings and strategic partnerships, particularly noteworthy being its collaboration with NVIDIA for AI development in life sciences. The company's reduced dependence on small to mid-sized biotechs compared to peers provides relative stability in uncertain market conditions.

IQVIA's growth strategy leverages several promising market opportunities, including the **expanding demand for decentralized clinical trials** and advanced analytics in healthcare. The company's extensive global data assets and analytics capabilities position it well to capitalize on increasing R&D complexity in the pharmaceutical industry. However, investors should note certain challenges, including exposure to pharmaceutical industry volatility and vulnerability to large-scale project cancellations. The company's complex organizational structure may also present integration challenges.

From a financial perspective, IQVIA demonstrates mixed indicators. While maintaining strong free cash flow and an active share repurchase program (\$425 million in Q1 2025), the company faces some concerns regarding short-term obligations exceeding liquid assets. The R&D Solutions backlog stands at **\$31.5 billion**, suggesting potential future revenue stability despite current industry headwinds.

Recent developments highlight IQVIA's focus on technological advancement, with the launch of custom-built AI agents utilizing NVIDIA technology for life sciences workflows. The company has raised its full-year 2025 revenue guidance to \$16.0-16.4 billion, though it has reset its long-range growth expectations to 6-9% on a constant currency basis, reflecting both opportunities and challenges in the evolving healthcare analytics landscape.



Valuation

Reporting Date	2022	2023	2024	2025	2026
Period Ending	31/12	31/12	31/12	31/12	31/12
Capitalization	38.1B	42.2B	35.7B	27.5B	27.5B
P/E Ratio	32.2	37.8	25.4	13.2	12.2
Div. Yield	0	0	0	0	-
Capitalization / Revenue	2.66	2.84	2.33	1.71	1.63
EV / Revenue	3.45	3.69	3.13	2.47	2.36
EV / EBITDA	17.9	20.2	16.9	10.5	9.82
EV / FCF	29.1	41.0	21.6	-	-
FCF Yield	0.04	0.03	0.05	-	-
Price / Book	7.12	7.27	5.12	4.61	-

- Forecast

Analyst Projections:

Analyst EPS Forecasts

Period Ending	Average	YoY Growth	Forward P/E	# of Analysts
2024	12.02	6.3%	13.2x	22
2025	13.05	9.9%	12.2x	22
2026	14.09	9.9%	11.3x	14

EPS Revisions Q2 2025




The chart above depicts the trend in analyst earnings per share (EPS) forecasts for the upcoming quarter. Analysts have reduced this quarter's expectations by 2.3% for EPS from \$3.18 per share to \$3.11 per share over the last 12 months. The company is expected to report earnings for Q2, 2025, on July 29, 2025.

Latest Ratings

Date	Analyst	Rating	Target
Feb 10, 25	RBC Capital Markets	-	\$270.00
Feb 07, 25	Barclays	-	\$235.00
Feb 03, 25	BTIG	Neutral	-
Dec 11, 24	Barclays	-	\$255.00
Dec 11, 24	RBC Capital Markets	-	\$270.00
Nov 05, 24	RBC Capital Markets	-	\$270.00
Nov 01, 24	RBC Capital Markets	-	\$270.00
Nov 01, 24	Barclays	-	\$255.00
Oct 29, 24	RBC Capital Markets	-	\$270.00
Oct 28, 24	Barclays	-	\$260.00



Y LTM Financials:



* Revenue segments are based on data from 2024-06-30 to 2025-03-31

* Income Statement is based on LTM data from 2024-03-31 to 2025-03-31

Income Statement

Date	2021	2022	2022	2024	LTM
Revenue	13,874	14,410	14,984	15,405	15,497
Operating Income	1,446	1,860	2,071	2,279	2,283
Net Income to Stockholders	966.0	1,091	1,358	1,373	1,334
Shares Outstanding	191.0	185.7	182.5	181.5	173.0
Diluted EPS	4.95	5.72	7.29	7.49	7.35
EBITDA	2,499	2,571	2,721	2,921	2,926

Balance Sheet


Date	2021	2022	2022	2024	LTM
Total Current Assets	4,763	4,981	5,596	5,829	5,911
Total Assets	24,689	25,337	26,681	26,899	27,322
Total Current Liabilities	5,241	5,578	6,491	6,957	7,179
Total Liabilities	18,647	19,572	20,569	20,832	21,337
Total Equity	6,042	5,765	6,112	6,067	5,985
Total Debt	12,462	13,011	13,947	14,484	14,538

Cash Flow Statement


Date	2021	2022	2022	2024	LTM
Cash from Operations	2,942	2,260	2,149	2,716	2,762
Cash from Investing	-2,103	-2,006	-1,603	-1,444	-1,435
Cash from Financing	-1,235	-329.0	-382.0	-878.0	-1,030
Levered Free Cash Flow	2,302	1,586	1,500	2,114	2,163

*In millions, except number of shares, which are reflected in thousands, and per share amounts.


Revenue, Market Cap, Price/sales



Net Income, EPS, Shares




Leverage and Debt





Q2 Financials



* Revenue segments are based on data from 2025-03-31

* Income Statement is based on LTM data from 2025-03-31

Income Statement

Date	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Revenue	3,737	3,814	3,896	3,958	3,829
Operating Income	521.0	548.0	578.0	632.0	525.0
Net Income to Stockholders	288.0	363.0	285.0	437.0	249.0
Shares Outstanding	182.0	182.2	182.3	181.5	176.3
Diluted EPS	1.56	1.97	1.55	2.42	1.40
EBITDA	785.0	817.0	856.0	935.0	790.0

Balance Sheet


Date	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Total Current Assets	5,651	5,622	5,632	5,829	5,911
Total Assets	26,574	26,398	27,180	26,899	27,322
Total Current Liabilities	6,448	6,620	6,992	6,957	7,179
Total Liabilities	20,230	19,684	20,213	20,832	21,337
Total Equity	6,344	6,714	6,967	6,067	5,985
Total Debt	13,894	13,593	13,952	14,484	14,538

Cash Flow Statement


Date	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Cash from Operations	522.0	588.0	721.0	885.0	568.0
Cash from Investing	-314.0	-221.0	-599.0	-310.0	-305.0
Cash from Financing	-106.0	-260.0	-137.0	-375.0	-258.0
Levered Free Cash Flow	377	445	571	721	426

*In millions, except number of shares, which are reflected in thousands, and per share amounts.


Revenue, Market Cap, Price/sales



Net Income, EPS, Shares



Leverage and Debt



Latest Wall Street Insights

Bull Case

- IQVIA's strategic investments in technology, particularly in artificial intelligence and advanced analytics, position the company at the forefront of innovation in the healthcare and life sciences industries.
- The collaboration with NVIDIA could lead to breakthrough applications of AI in drug discovery, clinical trial design, and real-world evidence analysis.
- As the healthcare industry continues to digitize and generate vast amounts of data, IQVIA's expertise in data analytics becomes increasingly valuable.
- Technology investments could lead to increased operational efficiency for IQVIA itself, improving profit margins and allowing the company to scale its operations more effectively.
- IQVIA's global presence in over 100 countries provides a strong foundation for expansion in emerging markets.
- Increasing healthcare spending in emerging markets is expected to create demand for IQVIA's services.
- Many emerging markets are becoming increasingly attractive locations for clinical trials, where IQVIA's expertise in managing global trials positions it well.
- Growing local pharmaceutical industries in emerging markets often require the types of services IQVIA provides.
- Adoption of advanced healthcare technologies in emerging markets creates demand for data analytics and technology solutions, areas where IQVIA has strong capabilities.

Bear Case

- Ongoing reorganizations within large pharmaceutical companies present a significant challenge for IQVIA, potentially leading to project delays, cancellations, or scope reductions.
- IQVIA has already experienced an uptick in cancellations and delays reported in the third quarter of 2024, which could continue or accelerate.
- As pharmaceutical companies streamline operations, they may internalize some services traditionally outsourced to CROs like IQVIA, potentially reducing the overall market size.
- The CRO industry is becoming increasingly competitive, with both established players and new entrants vying for market share.
- Companies like Veeva Systems are expanding their offerings, potentially encroaching on IQVIA's territory, particularly in the technology and analytics solutions segment.
- Increased competition could lead to pricing pressures and the need for increased investment in research and development to stay ahead of the curve.
- The trend towards specialization in certain therapeutic areas or types of clinical trials could allow smaller, more focused CROs to capture niche markets.
- If IQVIA fails to effectively respond to competitive pressures, it could result in a gradual erosion of its market share and a negative impact on its financial performance over time.

Additional Analyst Takeaways

- IQVIA's current market capitalization is \$23.7 billion, and the stock is trading near its 52-week low.
- According to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimate.
- The company's third quarter of 2024 saw an uptick in cancellations and delays affecting bookings and the mid-term revenue and EBITDA outlook.
- Management reported a subpar bookings ratio of 1.06x (compared to 1.22x excluding a significant cancellation) in Q3 2024.
- 15 analysts have revised their earnings downward for the upcoming period.
- IQVIA maintains healthy EBITDA of \$2.9 billion over the last twelve months.
- The company's long-range plan (LRP) has been reset to a growth rate of 6-9% on a constant currency basis.
- Initial guidance for 2025 suggests growth of 4-6%, excluding COVID-related business.
- IQVIA's total addressable market is valued at over \$300 billion.
- Management has indicated a willingness to engage in aggressive share repurchases, which could potentially drive significant upside to earnings per share (EPS) estimates for 2025 and beyond.
- InvestingPro confirms management has been actively buying back shares, with the company generating a strong free cash flow yield.



SWOT Analysis

Strengths

- Diverse portfolio of services across healthcare and life sciences
- Strong data analytics capabilities and extensive global data assets
- Presence in over 100 countries, providing global reach and local expertise
- Strategic partnerships with technology leaders like NVIDIA
- Less dependent on small to mid-sized biotechs compared to peers

Weaknesses

- Exposure to volatility in the pharmaceutical and biotechnology industries
- Vulnerability to large-scale project cancellations or delays
- Complex organizational structure may lead to integration challenges

Opportunities

- Expanding market for decentralized clinical trials
- Growing demand for real-world evidence and advanced analytics in healthcare
- Potential for expansion in emerging markets
- Increasing R&D complexity driving demand for specialized services
- AI and machine learning applications in drug discovery and development

Threats

- Ongoing reorganizations in large pharmaceutical companies
- Increasing competition from both established CROs and new entrants
- Regulatory changes affecting clinical trials and data privacy
- Potential for internalization of services by large pharmaceutical clients
- Economic downturns affecting R&D spending in the life sciences sector

Pro Tips

Tips that distill complex financial data into concise, actionable investment insights.

- 👉 Management has been aggressively buying back shares
- 👉 Valuation implies a strong free cash flow yield
- 👉 Prominent player in the Life Sciences Tools & Services industry
- 👉 Strong return over the last month
- 👉 Analysts predict the company will be profitable this year
- 👉 Profitable over the last twelve months

- 👎 Trading at a high P/E ratio relative to near-term earnings growth

- 👎 Short term obligations exceed liquid assets

- 👎 Does not pay a dividend to shareholders



Momentum & Technical Indicators


Price Momentum

Metric	IQV	Percentile	Score
Price % of 52 Week High	62.8%	58.3%	2.9
1 Month Price Total Return	15.8%	81.7%	4.1
1 Week Price Total Return	2.7%	68.7%	3.4
1 Year Price Total Return	-24.8%	43.2%	2.2
2 Week Price Total Return	-0.3%	58.8%	2.9
2 Year Price Total Return	-25.8%	54.3%	2.7
3 Month Price Total Return	-11.8%	35.1%	1.8
3 Week Price Total Return	7.7%	80.2%	4.0
3 Year Price Total Return	-25.8%	60.1%	3.0
4 Year Price Total Return	-35.3%	69.5%	3.5
5 Year Price Total Return	16.7%	79.7%	4.0
6 Month Price Total Return	-20.7%	37.4%	1.9


Peers

CRL	AVTR
59.1%	48.5%
9.9%	7.0%
3.4%	2.2%
-27.3%	-38.1%
-1.1%	0.3%
-27.2%	-31.2%
-5.1%	-16.6%
6.4%	4.9%
-33.6%	-57.0%
-59.2%	-61.9%
-11.6%	-19.0%
-19.5%	-36.8%


Technical Summary



Moving Averages



Technical Indicators



The Moving Average Score is based on various moving averages, both simple and exponential, with ranges from 5 to 200.

The Technical Score is calculated based on key technical indicators, including RSI, Stochastic, MACD, Williams %R, CCI, ATR, Highs/Lows, Ultimate Oscillator, ROC, and Bull/Bear Power, among others.

Peer Benchmarks:

Market and Yield Metrics

Metric	IQV	CRL	AVTR
Market Cap	27.5B	\$7.4B	\$9.3B
Price % of 52 Week High	0.63%	0.59%	0.48%
Div Yield	0%	0%	0%
Beta	1.29	1.48	1.05
1 Year Return	-0.25%	-0.27%	-0.38%

Growth Metrics

Metric	IQV	CRL	AVTR
Revenue Growth	0.03%	-0.02%	-0.03%
Revenue CAGR (5y)	0.07%	0.09%	0.02%
Net Income Growth	-0.02%	-1.04%	1.75%
Net Income CAGR (5y)	0.48%	-0.38%	0.80%
Revenue Forecast CAGR (5y)	0.06%	0.02%	0.03%
Net Income Forecast CAGR (5y)	0.16%	1.28%	0.09%

Financial Statement Metrics

Metric	IQV	CRL	AVTR
Revenue	\$15.5B	\$4.0B	\$6.7B
Gross Profit	\$5.4B	\$1.4B	\$2.2B
Operating Income	\$2.3B	\$536.9M	\$708.3M
Gross Profit Margin	0.35	0.35	0.34
Net Income to Common	\$1.3B	-\$31.6M	\$715.6M
ROE	0.22	-0.01	0.13
ROI	0.10	0.07	0.05
ROA	0.05	-0.00	0.06
Total Assets	27.3B	\$7.6B	\$12.3B
Total Debt	14,538	\$3.0B	\$4.1B

Valuation Metrics

Metric	IQV	CRL	AVTR
P/E Ratio (LTM)	20.7	-237.1	13.2
PEG Ratio	78.3	2.14	0.07
Price / Book	4.61	2.34	1.54
Price / LTM Sales	1.78	1.86	1.41
Analyst Upside	0.18%	0.05%	0.21%
Fair Value Upside	0.25%	0.19%	0.22%



Earnings Call - Q1 2025

Date: 05/06/25

- IQVIA Holdings Inc. reported a strong Q1 2025 performance with adjusted EPS of \$2.70, surpassing the forecast of \$2.64.
- Revenue for Q1 2025 was \$3.83 billion, exceeding the expected \$3.78 billion.
- The company raised its full-year revenue guidance to \$16.0-\$16.4 billion.

Bullish Highlights

- IQVIA's adjusted EPS increased by 6.3% year-over-year.
- Revenue for Q1 2025 grew by 2.5% reported and 3.5% at constant currency.
- The company is expanding AI deployments and strategic partnerships to drive future performance.
- CEO Ari Bousvi expressed optimism about the industry's resilience and growth prospects.
- IQVIA's diversified portfolio and leadership in the real-world evidence market position it well in the biopharmaceutical sector.

Q&A Highlights

- Analysts inquired about the strength in the real-world evidence market and its durability for the rest of the year.
- Discussions on margin opportunities highlighted the impact of FX and cost reduction initiatives, including AI deployment.
- Concerns about vendor consolidation trends in the RDS market were addressed, emphasizing stable RFP flow and hit rates.
- Questions on the operating environment's uncertainty and its impact on short-cycle business in TAS were discussed.
- The potential for mega trial delays and the strategic approach to capitalize on real-world evidence opportunities were explored.

- Despite positive earnings, IQVIA's stock price decreased by 0.82%.
- Strong free cash flow of \$426 million and significant share repurchases were noted.
- IQVIA remains a key player in the life sciences industry, with a focus on strategic acquisitions and operational execution.

Bearish Highlights

- IQVIA's stock experienced a slight decline of 0.82% in pre-market trading despite exceeding earnings expectations.
- Analysts have revised their earnings expectations downward for the upcoming period.
- Regulatory changes and market saturation are potential risks that could affect margins.
- Supply chain disruptions and R&D fluctuations pose challenges to future growth.
- Broader economic uncertainties, such as inflation or interest rate changes, could impact investment and spending in the sector.

Misses

- The company experienced delayed decision-making by customers on new programs, reflecting macroeconomic caution.
- The R&D Solutions market faced turbulence due to funding environment deterioration, particularly in early-stage projects.
- An unusually high number of EVP awards were contracted but not included in bookings due to unsecured funding.
- The precise impacts of recent U.S. government initiatives on the sector are uncertain and could affect future earnings.



Top News, last 60 days:

[IQVIA launches AI agents using NVIDIA technology for life sciences workflows](#)

June 11, 2025

- IQVIA (NYSE:IQV), a \$27.6 billion market cap company in Life Sciences Tools & Services, has introduced custombuilt AI agents at GTC Paris that leverage NVIDIA technology to enhance workflows for life sciences companies.
- The AI agents utilize NVIDIA NIM Agent Blueprints, NeMo Customizer, and NeMo Guardrails for applications including target identification, clinical data review, and healthcare professional engagement.
- This development follows a strategic collaboration announced in January between IQVIA and NVIDIA to build custom foundation models and AI workflows for accelerating research and clinical development.
- IQVIA reported Q1 2025 earnings with adjusted EPS of \$2.70 (exceeding the \$2.64 forecast) and revenue of \$3.83 billion (above the expected \$3.78 billion).
- The company has raised its fullyear 2025 revenue guidance to a range of \$16.0 to \$16.4 billion and priced a \$2 billion offering of senior notes due in 2032.

Importance - 6/10 Positive 📈

[IQVIA Holdings faces industry headwinds while pursuing growth through technology investments](#)

May 25, 2025

- IQVIA Holdings Inc. (NYSE:IQV), a global leader in healthcare analytics and clinical research services, is facing challenges with a market capitalization of \$23.7 billion and trading near its 52week low as of May 25, 2025.
- The company reported a subpar bookings ratio of 1.06x in Q3 2024, with an uptick in cancellations and delays affecting bookings and midterm revenue outlook.
- IQVIA has reset its longrange plan to a growth rate of 69% on a constant currency basis, with initial 2025 guidance suggesting growth of 46% excluding COVIDrelated business.
- The company is investing in technology partnerships, including a collaboration with NVIDIA, to leverage AI capabilities across its business lines and potentially open new revenue streams.
- Recent analyst price targets include Barclays at \$235.00 (February 7, 2025) and RBC Capital Markets at \$270.00 (February 10, 2025), with BTIG maintaining a Neutral rating.

Importance - 6/10 Neutral

[IQVIA Reports Q1 2025 Results with 2.5% Revenue Growth and EPS Beat](#)

May 06, 2025

- IQVIA Holdings Inc. released its Q1 2025 financial results on Tuesday, May 6, 2025, reporting revenue of \$3.83 billion, up +2.5% yearoveryear on an actual currency basis and +3.5% at constant currency.
- Adjusted earnings per share reached \$2.70, up +6.3% from Q1 2024 and exceeding analyst forecasts of \$2.64, while GAAP net income declined to \$249 million from \$288 million in the same period last year.
- Technology & Analytics Solutions emerged as the growth driver with revenue up +6.4%, while Research & Development Solutions showed minimal growth at just +0.3% and Contract Sales & Medical Solutions declined 4.2% yearoveryear.
- IQVIA's R&D Solutions backlog expanded to \$31.5 billion in Q1 2025, representing a +4.8% increase from Q1 2024, suggesting potential for future revenue acceleration despite current modest growth.
- The company raised its fullyear 2025 revenue guidance to between \$16.0 billion and \$16.4 billion, while maintaining its adjusted EBITDA guidance of \$3.77\$3.89 billion.

Importance - 6/10 Neutral

[IQVIA Holdings Beats Q1 2025 Earnings Expectations Despite Industry Uncertainty](#)

May 06, 2025

- IQVIA Holdings reported Q1 2025 adjusted EPS of \$2.70, exceeding the forecast of \$2.64, and revenue of \$3.83 billion, surpassing the expected \$3.78 billion.
- Despite positive results, IQVIA's stock experienced a slight decline of 0.82% in premarket trading on Tuesday, May 6, 2025, closing at \$152.30.
- Revenue for Q1 2025 grew by 2.5% reported and 3.5% at constant currency, with Technology and Analytics Solutions (TAS) segment growing 7.6% at constant currency led by doubledigit growth in realworld evidence.
- IQVIA raised its fullyear 2025 revenue guidance to \$16.0\$16.4 billion while reaffirming its adjusted EBITDA guidance of \$3.765\$3.885 billion.
- CEO Ari Bousvi noted that while the R&D Solutions business is experiencing uncertainty due to U.S. administration pronouncements, the company remains confident in the life sciences industry's resilience.
- R&D Solutions backlog reached a record \$31.5 billion at the end of Q1 2025, growing 4.8% compared to the prior year, despite delays in decisionmaking by customers on new programs.
- The company repurchased \$425 million of its shares in Q1 2025, with approximately \$2.6 billion remaining under the current repurchase program.

Importance - 6/10 Neutral



[IQVIA Reports Strong Q1 2025 Results with Revenue Growth and Raised Guidance](#)

May 06, 2025

- IQVIA reported Q1 2025 revenue of \$3,829 million, up 2.5% on a reported basis and 3.5% at constant currency compared to Q1 2024.
- The company posted Q1 GAAP Net Income of \$249 million with GAAP Diluted EPS of \$1.40, while Adjusted EBITDA was \$883 million (up 2.4% yearoveryear) and Adjusted Diluted EPS was \$2.70 (up 6.3% yearoveryear).
- Technology & Analytics Solutions (TAS) revenue grew 6.4% on a reported basis to \$1,546 million, while R&D Solutions contracted backlog increased 4.8% yearoveryear to \$31.5 billion.
- Operating Cash Flow was \$568 million and Free Cash Flow was \$426 million (up 13% yearoveryear), with the company repurchasing \$425 million of common stock during Q1.
- IQVIA raised its fullyear 2025 revenue guidance by \$275 million to between \$16,000 million and \$16,400 million due to favorable foreign currency exchange rates, while reaffirming profit guidance.

Importance - 6/10

Neutral

[IQVIA Unveils AI Agents for Life Sciences Using NVIDIA Technology](#)

June 11, 2025

- IQVIA Holdings (IQV) unveiled new custombuilt AI agents using NVIDIA technology at GTC Paris on Wednesday, 20250611.
- The AI agents are designed to enhance workflows and accelerate insights for life sciences across target identification, clinical data review, literature review, market assessment, and HCP engagement.
- IQVIA is leveraging NVIDIA NIM Agent Blueprints, NeMo Customizer, and NeMo Guardrails to develop agents that help find breakthroughs and simplify operations across life sciences.
- The company announced a strategic collaboration with NVIDIA in January 2025 to build custom foundation models and agentic AI workflows to accelerate research, clinical development and access to new treatments.
- IQVIA will host its TechIQ 2025 conference in September in London, featuring insights from industry leaders including NVIDIA.

Importance - 5/10

Positive 🟢

Disclaimer

This Investing.com Pro Research Report (the "Report") is a summary report provided to you for general informational purposes only, and should not be considered as investment, legal, tax, accounting or other advice. Investing.com is not a licensed securities dealer, broker, investment adviser, financial service provider or investment bank and we urge you to consult a licensed broker, investment advisor or other appropriate advisor before making any investment. This information does not represent a recommendation to buy or sell any stock or other financial instrument, nor does it reflect the views of Investing.com or its employees. NEITHER INVESTING.COM, NOR ANY OF ITS AFFILIATES AND THEIR RESPECTIVE OFFICERS, EMPLOYEES OR SERVICE PROVIDERS, TAKE ANY RESPONSIBILITY FOR THE RESULTS OF ANY INVESTMENT MADE BY YOU BASED ON THE INFORMATION PROVIDED IN THE REPORT, AND YOU ALONE ASSUME SOLE RESPONSIBILITY FOR ANY SUCH INVESTMENT.

Information included in this Report is provided to us by third party suppliers, and was not independently verified by Investing.com. The Report is based on the most recent data available to us, such as quarterly/annual financial reports of the company, but may not necessarily be the most recent data publicly available. The information included is not real-time data. Certain Portions of this Report are generated by artificial intelligence tools. THE INFORMATION HEREIN IS PROVIDED "AS IS" AND WE DO NOT GUARANTEE OR REPRESENT THAT THE INFORMATION HEREIN IS ACCURATE, COMPLETE, RELIABLE, SUITABLE FOR ANY SPECIFIC PURPOSE. The information included herein is solely indicative and should not be relied on for trading purposes.

It is prohibited to reproduce, publish, display, modify, transmit or distribute the data contained above without our explicit prior written permission. The Report is provided for your personal use only, and is not to be shared with others. All intellectual property rights in the Report are reserved by Investing.com or its third party providers.